Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Morita, S.
Right arrow Articles by Ohashi, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Morita, S.
Right arrow Articles by Ohashi, Y.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Japanese Journal of Clinical Oncology 33:470-476 (2003)
© 2003 Foundation for Promotion of Cancer Research

Influence of Clinical Parameters on Quality of Life During Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer: Application of a General Linear Model

Satoshi Morita1, Kunihiko Kobayashi2, Kenji Eguchi3, Taketoshi Matsumoto4, Masahiko Shibuya5, Yasufumi Yamaji6, Junichi Sakamoto1 and Yasuo Ohashi7,+

1 Department of Epidemiological and Clinical Research Information Management, Kyoto University Graduate School of Medicine, Kyoto, 2 Department of Pulmonary Medicine, Saitama Cancer Center, Saitama, 3 Division of Pulmonary Medicine, Tokai University School of Medicine, Kanagawa, 4 Department of Respiratory Disease, Musashigaoka Hospital, Kumamoto, 5 Division of Respiratory Medicine, Tokyo Metropolitan Komagome Hospital, Tokyo, 6 Department of Internal Medicine, Mitoyo General Hospital, Kagawa and 7 School of Health Sciences and Nursing, University of Tokyo, Tokyo, Japan

Objective: The aim of this study was to determine the relative influence of physician-assessed clinical parameters, including non-hematological adverse events and performance status, on quality of life (QOL) during chemotherapy.

Methods: QOL questionnaires consisting of four domains (functional, physical, mental and psychosocial) were self-administered every week during chemotherapy by patients with advanced non-small cell lung cancer in two phase III clinical trials; 377 patients who completed the questionnaires at baseline and at least once during the first course of therapy were analyzed. A general linear model was applied, where the four domains and the clinical parameters (nausea/vomiting, anorexia, diarrhea, fever, peripheral neuropathy and performance status) were used as the response and explanatory variables, respectively. In this model, the multi-dimensional and longitudinal aspects of QOL data were taken into account.

Results: All four domains were significantly affected by the occurrence of nausea/vomiting, anorexia and diarrhea. No influence of peripheral neuropathy on the domains was detected. Performance status was significantly related to the domains (except the psychosocial domain).

Conclusion: This study revealed, by examination of multi-dimensional repeated QOL data, that clinical parameters had significant effects on QOL in patients undergoing chemotherapy. Our findings suggest that supportive care to control non-hematological adverse events, especially gastrointestinal, could maintain overall QOL in cancer patients in an earlier phase of chemotherapy.

+ For reprints and all correspondence: Satoshi Morita, Department of Epidemiological and Clinical Research Information Management, Kyoto University Graduate School of Medicine, Yoshidakonoe-cho, Sakyo-ku, Kyoto 606-8501, Japan. E-mail: smorita{at}pbh.med.kyoto-u.ac.jp


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
The OncologistHome page
R. J. Gralla
Quality-of-Life Considerations in Patients with Advanced Lung Cancer: Effect of Topotecan on Symptom Palliation and Quality of Life
Oncologist, December 1, 2004; 9(suppl_6): 14 - 24.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.